logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

WCLC 2019 – 5-year survival in advanced NSCLC: greater than 4-fold increase with nivolumab over docetaxel

According to a pooled analysis of CheckMate 017 and 057 studies, nivolumab leads to better survival outcomes and is well tolerated in the long-term.